Polypyrimidine Tract Binding Protein: A Universal Player in Cancer Development.
Curr Mol Med 2023:CMM-EPUB-135530. [PMID:
37877563 DOI:
10.2174/0115665240251370231017053236]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2023] [Revised: 08/31/2023] [Accepted: 09/05/2023] [Indexed: 10/26/2023]
Abstract
OBJECTIVES
Polypyrimidine tract binding protein is a 57-Kda protein located in the perinucleolar compartment where it binds RNA and regulates several biological functions through the regulation of RNA splicing. Numerous research articles have been published that address the cellular network and functions of PTB and its isoforms in various disease states.
METHODOLOGY
Through an extensive PubMed search, we attempt to summarize the relevant research into this biomolecule.
RESULTS
Besides its roles in embryonic development, neuronal cell growth, RNA metabolism, apoptosis, and hematopoiesis, PTB can affect cancer growth via several metabolic, proliferative, and structural mechanisms. PTB overexpression has been documented in several cancers where it plays a role as a novel prognostic factor.
CONCLUSION
The diverse carcinogenic effect opens an argument into its potential role in inhibitory targeted therapy.
Collapse